In a world where clinical data is more exposed than ever, are we really protecting what matters most, our patients, trial participants and our intellectual property? In this episode of Kill It With Data, host Darshan Kulkarni sits down with Nirpal Virdee, Medispend’s GM of Regulatory Science, a leading voice in regulatory strategy and data anonymization, to unpack the uncomfortable truth: by the time regulators publish our data, most of the “prized cow” IP has already left the barn. Together, they explore why so many organizations still treat IP protection as an afterthought, how that undermines R&D investment and market advantage, and why executives often don’t even have a clear answer to the basic question: What exactly are we trying to protect?
This conversation goes beyond buzzwords and compliance checklists. Darshan and Nirpal dig into the friction between transparency and protection, EMA vs. FDA philosophies, FOIA-style redactions, the reality that competitors and litigators are often the ones mining raw data, not patients, and what it really takes to build a purposeful IP strategy from day one. They discuss practical ways to involve patients meaningfully, use technology for traceability and control, and design disclosure workflows that safeguard both innovation and corporate resilience. If you work in pharma, biotech, legal, or regulatory affairs and you’re wrestling with how to balance openness with protecting confidential information, this is a deep dive you can’t afford to skip.
Learn more about Confidential Information Management (CIM), or connect with our team to see what IP protection looks like in practice.